Endo Health price target lowered to $36 from $42 at Stifel Stifel reduced its price target on Endo Health after the FDA denied the company's Citizen Petition on OpanaER. The firm was surprised by the FDA's decision ,and thinks the company will now have to restructure, but keeps a Buy rating based on valuation.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo shares remain overvalued, says Cantor Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.